- Brainomix 360 Stroke Next Generation received the prestigious Red Dot Design Award for ease of use and innovation.
- Industry-first net water intake functionality provides deeper insight into stroke injury and informs treatment decisions.
- The new research will be presented at ISC, and three abstracts will be awarded the prestigious Paul Dudley White International Scholar Award from the American Heart Association.
oxford, england, chicago, February 2, 2026 /PRNewswire/ — Brainomix, a global leader and pioneer in AI-powered imaging tools in stroke and pulmonary fibrosis, announces the launch of the new Brainomix 360 next-generation platform at the International Stroke Conference (ISC), February 4-6, 2026 at the Ernest N. Morial Convention Center in New Orleans.
Brainomix 360 Stroke Next Generation includes a new net water absorption feature.
The new platform and feature upgrades offer first-of-its-kind net water uptake (NWU) capabilities using routine non-contrast CT (NCCT) scans and an award-winning user experience. The company will also present five summaries, including oral presentations, highlighting the value and impact of Brainomix 360 Stroke and further strengthening its extensive evidence base.
Brainomix 360 Stroke Next Generation sets new standards in user experience and innovation and was recently awarded the prestigious Red Dot Design Award. Selected from more than 20,000 entries across 60 countries, Brainomix joins previous winners including Apple, Sony, and Samsung in the award, which recognizes excellence in ease of use, safety, and innovative design. With enhanced DICOM viewing capabilities and AI-powered patient-specific insights, the platform supports streamlined workflows and enables faster, more confident and informed decision-making.
Brainomix’s best-in-class AI algorithms also include industry-first regulated Net Water Withdrawal (NWU) functionality. Fully automated percentage-based NWU output extends Brainomix’s leadership in simple imaging, extracting expert-level insights from routine non-contrast CT scans to support improved treatment and transport decision-making.
Dr. George HurstonChief Medical and Innovation Officer at Brainomix and Stroke Consultant at Oxford University Hospitals said: “We are pleased to introduce this latest innovation in stroke AI imaging, building on our universally available CT imaging expertise. The automated net fluid uptake output complements Brainomix’s unique ischemic core volume and e-ASPECTS capabilities, providing routine non-contrast CT imaging to clinicians in all hospital settings. Using scans to provide deeper insight into stroke injuries, we hope this latest advancement will improve physician confidence when treating even the most severe strokes in a world where clinical uncertainty is causing stroke patients to miss out on effective treatment.”
Three of the abstracts presented at ISC were awarded the Paul Dudley White International Scholar Award, which recognizes the authors of the highest-ranking accepted abstracts from around the world.
Building on Brainomix’s rich academic heritage and extensive global research network, these latest studies include:
- A national cost-effectiveness analysis showed that widespread implementation of Brainomix 360 Stroke could significantly improve thrombolysis and thrombectomy rates, leading to improved functional outcomes, improved long-term health quality, and net financial benefits.
- Validation of an image-based model to automate follow-up infarct volume (FIV) segmentation.
- Future performance validation of Brainomix 360 Triage LVO.
- Clinical impact of collateral hemodynamics during interhospital transport.
- A new approach to enhance the detection of stroke mimics.
For more information about these abstracts, including presentation times and locations, please visit the Brainomix website.
About Brain Mix
Brainomix is a global pioneer in AI medical imaging, enabling precision medicine for better treatment decisions in stroke and pulmonary fibrosis. The company’s flagship product, Brainomix 360 Stroke, is the world’s first fully automated AI imaging platform designed to assess acute stroke at every point in the patient pathway, facilitating more definitive treatment and transfer decisions for patients in all hospitals, regardless of local resources or expertise. Brainomix 360 e-Lung technology applies AI-driven CT biomarkers to identify, monitor, and predict disease progression in pulmonary fibrosis. Founded as a spin-out from the University of Oxford, Brainomix operates in more than 20 countries, with offices in the UK, Ireland and the US.
For more information about Brainomix and its technology, please visit: www.brainomix.com,follow me Twitter, linkedin and facebook.
contact address
Jeff Wyrtzen, Chief Marketing Officer
[email protected]
Phone +44 (0)1865 582730
Inquiries from US media
Dr. Jason Braco
Lifecy Communications
[email protected]
UK and European media inquiries
Sue Charles
charles consultant
[email protected]
Photo – https://mma.prnewswire.com/media/2874606/Brainomix_360.jpg
Logo – https://mma.prnewswire.com/media/1989193/5746793/Brainomix_Logo.jpg
Source Brainomix
